Donald J Marsh

US Patent:

7259289, Aug 21, 2007

Filed:

Mar 19, 2002

Appl. No.:

10/472629

Inventors:

Su Qian - Edison NJ, US
Donald J. Marsh - Hillsborough NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A01K 67/027
G01N 33/00

US Classification:

800 18, 800 3, 800 8, 800 9, 800 14

Abstract:

The present invention features viable MCH1R deficient mice. MCH1R deficient mice contain an alteration in one or both MCH1R alleles that substantially reduces expression of a functional MCH1R from the altered allele. Preferably, MCH1R deficient mice are MCH1R −/− knockout mice.

US Patent:

7928058, Apr 19, 2011

Filed:

Feb 16, 2007

Appl. No.:

12/223942

Inventors:

Ranabir Sinha Roy - Edison NJ, US
Elisabetta Bianchi - Rome, IT
Antonello Pessi - Rome, IT
Paolo Ingallinella - Pomezia, IT
Donald J. Marsh - Hillsborough NJ, US
George J. Eiermann - Marlboro NJ, US
Yingjun Mu - Fanwood NJ, US
Yun-Ping Zhou - East Brunswick NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A. - Pomezia (Roma)

International Classification:

A61K 38/00

US Classification:

514 11, 514 117, 514 213, 530300

Abstract:

Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.

US Patent:

8268779, Sep 18, 2012

Filed:

Mar 21, 2011

Appl. No.:

13/052270

Inventors:

Ranabir Sinha Roy - Edison NJ, US
Elisabetta Bianchi - Rome, IT
Antonello Pessi - Rome, IT
Paolo Ingallinella - Pomezia, IT
Donald J. Marsh - Hillsborough NJ, US
George J. Eiermann - Marlboro NJ, US
Yingjun Mu - Fanwood NJ, US
Yun-Ping Zhou - East Brunswick NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 38/00
A61P 3/10

US Classification:

514 48, 514 49, 514 68, 514 69, 530300

Abstract:

Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.

US Patent:

20050069883, Mar 31, 2005

Filed:

Sep 20, 2002

Appl. No.:

10/488758

Inventors:

Andrew Howard - Park Ridge NJ, US
Andreas Sailer - Edison NJ, US
Jie Pan - Plainsboro NJ, US
Tung Fong - Somerset NJ, US
Donald Marsh - Hillsborough NJ, US

International Classification:

A61K038/24
C12Q001/68
C07H021/04
C07K014/575

US Classification:

435006000, 435069100, 435320100, 435325000, 514012000, 530399000, 536023500

Abstract:

The present invention features MCH-1R antagonist binding proteins. MCH-1R antagonist binding proteins described herein are based on an MCH-1R having one or more alterations to the second intracellular loop or carboxy terminus that render the receptor substantially inactive to MCH binding. An MCH-1R antagonist binding protein can bind MCH-1R antagonists, but does not exhibit high affinity MCH binding and is not activated by the MCH.

US Patent:

20120165503, Jun 28, 2012

Filed:

Dec 18, 2009

Appl. No.:

13/202524

Inventors:

Paul E. Carrington - Rahway NJ, US
George Eiermann - Rahway NJ, US
Donald Marsh - Rahway NJ, US
Joseph Metzger - Rahway NJ, US
Alessandro Pocai - Rahway NJ, US
Ranabir Sinha Roy - Rahway NJ, US
Bianchi Bianchi - Pomezia, IT
Paolo Ingallinella - Pomezia, IT
Antonello Pessi - Pomezia, IT
Alessia Santoprete - Pomezia, IT
Elena Capito - Pomezia, IT
Richard Dimarchi - Indianapolis IN, US
Brian Ward - Bloomington IN, US

International Classification:

C07K 14/605

US Classification:

530308

Abstract:

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonistm are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.